A narrow yes on the peptides, and the question underneath it

Back in June we wrote about a meeting that hadn't happened yet. The FDA's Pharmacy Compounding Advisory Committee was scheduled to spend July 23 and 24 weighing whether several of the most-discussed peptides could move onto the list of substances that licensed compounding pharmacies are allowed to prepare. The argument then was simple: watch the discussion, not the vote, because the interesting part is how a regulator handles thin evidence against loud demand.

The meeting has now happened. The votes are worth reporting, and so is the thing that got said in the middle of them.

What the panel decided

On July 23 the committee voted to recommend four peptides for the 503A bulks list. BPC-157, KPV, and TB-500 each cleared by 8 to 6, with an abstention. MOTS-c passed 7 to 5. None were voted down. The following day the panel took up three more, including Epitalon and Semax, continuing the same exercise.

Two things about those numbers. First, they are close. An 8-6 vote is not a field waving something through; it is a room that disagreed and barely tipped. Second, the votes are advisory and non-binding. The FDA does not have to follow them, and even if it wants to, adding a substance to the list requires a formal rulemaking process that can run for months or longer. Nothing changed at a pharmacy counter on July 23. A committee made a recommendation, and the slower machinery hasn't moved yet.

The question underneath the vote

Here is the part that stayed with us. The recommendations passed over the objections of the FDA's own career scientists, and the objection was not really about benefit. It was about identity. What, precisely, is the substance being approved?

For a compounding list, that is not a philosophical question. It decides what a pharmacist is legally permitted to put in a vial. BPC-157 alone was nominated as two separate entries, the free base and the acetate salt, because the agency treats them as different substances. Reviewers raised the absence of standardized chemical definitions for compounds that circulate under a single familiar name. One panelist, voting yes, summed up the unease more plainly than any briefing document: "I'm voting on something here, but I don't know what that something is."

That sentence is the whole tension in one line. You can believe wider access belongs in regulated pharmacies rather than the gray market, and still notice that the thing being waved through isn't fully pinned down.

Why a narrow yes still isn't evidence

It is tempting to read a favorable vote as a quiet signal that the science arrived. It didn't. The committee was answering a procedural question, whether a licensed pharmacist may prepare these substances under prescription, not a clinical one. Permission to compound is a statement about oversight and acceptable risk. It is not a finding that a peptide does what its fans say.

The controlled human data for most of these names remains thin. One member who voted no made the point through a number every honest researcher keeps in view: roughly 30% of patients on placebo report a response. When the evidence base is mostly animal work and self-reported improvement, that baseline is not a footnote, it is the thing a real trial exists to see past. A more open pathway does nothing to fill that gap. If anything it widens the distance between how available a compound is and how well anyone understands it.

How to hold it

The two clocks from June are still the useful frame. Regulation moves on the timeline of meetings and rulemaking, which can shift in a single summer. Evidence moves on the timeline of trials, which takes years. This month the first clock jumped, narrowly, and the second one didn't. The responsible read is not "a panel said yes, so it must be good." It is closer to what one of the yes-voters admitted out loud: the door is being opened before anyone can say with precision what is walking through it.

Worth following. Still not a verdict on whether any of this works.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.